Activated human γδ T cells as stimulators of specific CD8+ T-cell responses to subdominant epstein barr virus epitopes: Potential for immunotherapy of cancer

Journal of Immunotherapy

Volumn 32, Issue 3, 2009, Pages 310-321

  Landmeier, Silke ^a   Altvater, Bianca ^a   Pscherer, Sibylle ^a   Juergens, Heribert ^a   Varnholt, Lena ^a   Hansmeier, Anna ^a   Bollard, Catherine M ^b   Moosmann, Andreas ^c   Bisping, Guido ^d   Rossig, C ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

Antigen presentation; Human; Immunotherapy; T cells

Indexed keywords

ARGINYLALANYLLYSYLPHENYLALANYLLYSYLGLUTAMINYLLEUCYLLEUCINE; EPITOPE; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS LYTIC CYCLE ANTIGEN; GAMMA INTERFERON; HLA ANTIGEN; LATENT MEMBRANE PROTEIN 2A; PHENYLALANYLLEUCYLTYROSYLALANYLLEUCYLALANYLLEUCYLLEUCYLLEUCINE; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; LYMPHOCYTE ANTIGEN RECEPTOR; VIRUS ANTIGEN;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MEMORY T LYMPHOCYTE; OPEN READING FRAME; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; BIOSYNTHESIS; DRUG EFFECT; EPSTEIN BARR VIRUS; GENETIC TRANSDUCTION; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; TUMOR CELL LINE; VIROLOGY; VIRUS INFECTION;

ANTIGEN-PRESENTING CELLS; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DIPHOSPHONATES; EPITOPES; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMIDAZOLES; IMMUNOTHERAPY; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; TRANSDUCTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67449105693     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31819b7c30     Document Type: Article

References (50)

1. Bollard CM, Gottschalk S, Leen AM, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007;110:2838-2845.
2. Heslop HE, Ng CYC, Li CF, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2:551-555.
3. Straathof KC, Leen AM, Buza EL, et al. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J Immunol. 2005;175:4137-4147.
4. Huang AYC, Golumbek P, Ahmadzadeh M, et al. Role of bone-marrow-derived cells in presenting MHC class I-restricted tumor-antigens. Science. 1994;264:961-965.
5. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5:296-306.
6. Maecker B, Mougiakakos D, Zimmermann M, et al. Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients. Leukemia. 2006;20:645-649.
7. Maus MV, Thomas AK, Leonard DGB, et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol. 2002;20: 143-148.
8. Oelke M, Maus MV, Didiano D, et al. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med. 2003;9: 619-624.
9. Schultze JL, Michalak S, Seamon MJ, et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest. 1997;100: 2757-2765.
10. Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gamma delta T cells. Science. 2005;309:264-268.
11. Kunzmann V, Bauer E, Wilhelm M. Gamma/delta T-cell stimulation by pamidronate. N Engl J Med. 1999;340:737-738.
12. Tanaka Y, Morita CT, Tanaka Y, et al. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature. 1995;375:155-158.
13. Boismenu R, Havran WL. Gamma delta T cells in host defense and epithelial cell biology. Clin Immunol Immunopathol. 1998; 86:121-133.
14. Hoshino T, Ohta A, Nakao M, et al. TCR gamma delta+ T cells in peripheral blood of patients with adult Still's disease. J Rheumatol. 1996;23:124-129.
15. Fisch P, Malkovsky M, Kovats S, et al. Recognition by human V gamma 9/V delta 2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells. Science. 1990;250:1269-1273.
16. Gober HJ, Kistowska M, Angman L, et al. Human T cell receptor gamma delta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003;197:163-168.
17. Nanno M, Seki H, Mathioudakis G, et al. Gamma/delta T cell antigen receptors expressed on tumor-infiltrating lymphocytes from patients with solid tumors. Eur J Immunol. 1992;22: 679-687.
18. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol. 1997;15:405-431.
19. Herbst H, Dallenbach F, Hummel M, et al. Epstein-Barr virus latent membrane-protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci USA. 1991;88: 4766-4770.
20. Kuppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol. 2003;3:801-812.
21. Niedobitek G. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. J Clin Pathol Mol Pathol. 2000;53:248-254.
22. Niedobitek G, Kremmer E, Herbst H, et al. Immunohisto-chemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Blood. 1997;90:1664-1672.
23. Gahn B, Siller-Lopez F, Pirooz AD, et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: A potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer. 2001;93:706-713.
24. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet. 1995;345:9-13.
25. Kinsella TM, Nolan GP. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther. 1996;7:1405-1413.
26. Riviere I, Brose K, Mulligan RC. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci USA. 1995;92:6733-6737.
27. Rossig C, Bollard CM, Nuchtern JG, et al. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer. 2001;94:228-236.
28. Rischer M, Pscherer S, Duwe S, et al. Human gamma delta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. Br J Haematol. 2004;126:583-592.
29. + cytotoxic T cells exert tumor-specific effector function. Cancer Res. 2007;67: 8335-8343.
30. Hislop AD, Annels NE, Gudgeon NH, et al. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med. 2002;195:893-905.
31. Lee SP, Thomas WA, Murray RJ, et al. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol. 1993;67:7428-7435.
32. Croft M, Dubey C. Accessory molecule and costimulation requirements for CD4 T cell response. Crit Rev Immunol. 1997; 17:89-118.
33. Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human gamma delta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 2007;67:7450-7457.
34. Pudney VA, Leese AM, Rickinson AB, et al. CD8(+) immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J Exp Med. 2005;201:349-360.
35. Tsang JYS, Chai JG, Lechler R. Antigen presentation by mouse CD4(+) T cells involving acquired MHC class II peptide complexes: another mechanism to limit clonal expansion? Blood. 2003;101:2704-2710.
36. Laichalk LL, Thorley-Lawson DA. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol. 2005;79:1296-1307.
37. Lee SP, Brooks JM, Al Jarrah H, et al. CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1. J Exp Med. 2004;199:1409-1420.
38. Leen A, Ratnayake M, Foster A, et al. Contact-activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells. J Immunother. 2007;30:96-107.
39. Adamopoulou E, Diekmann J, Tolosa E, et al. Human CD4(+) T cells displaying viral epitopes elicit a functional virus-specific memory CD8(+) T cell response. J Immunol. 2007;178:5465-5472.
40. Atanackovic D, Matsuo M, Ritter E, et al. Monitoring CD4(+) T cell responses against viral and tumor antigens using T cells as novel target APC. J Immunol Methods. 2003; 278:57-66.
41. Foster AE, Leen AM, Lee T, et al. Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12. J Immunother. 2007;30:506-516.
42. Quintarelli C, Vera JF, Savoldo B, et al. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007; 110: 2793-2802.
43. Wilhelm M, Kunzmann V, Eckstein S, et al. Gamma delta T cells for immune therapy of patients with lymphoid malignancies. Blood. 2003;102:200-206.
44. Angelini DF, Borsellino G, Poupot M, et al. Fc gamma RIII discriminates between 2 subsets of V gamma 9V delta 2 effector cells with different responses and activation pathways. Blood. 2004;104:1801-1807.
45. Chan CW, Crafton E, Fan HN, et al. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med. 2006;12:207-213.
46. Stary G, Bangert C, Tauber M, et al. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med. 2007;204:1441-1451.
47. Taieb J, Chaput N, Menard C, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med. 2006; 12:214-219.
48. Feuerer M, Beckhove P, Bai L, et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med. 2001;7:452-458.
49. Greiner J, Schmitt M, Li L, et al. Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood. 2006;108: 4109-4117.
50. Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6:1018-1023.